Cara Corp (TVRD): Net earnings per share (EPS TTM)

TVRD (Cara Therapeutics Inc) - company brandmark

The growth of Cara Therapeutics Inc (TVRD) is based on the expansion of the drug Korsuva within the nephrology segment. Net income per share over the last 12 months confirms this resilience, where -2.70 describes the current status of the metric. Development has been bolstered by the automation of substance synthesis, while batch production has been entrusted to certified contract centers, optimizing the company's operating expenses.

TVRD Cara Corp Earnings per share for the last 12 months (07/04/2022 - 11/18/2026)

Analytical breakdowns and data insights for company Cara Pharma (TVRD)

- stock price and consensus target price:
Initial company analysis:caratherapeutics.com (TVRD)
Flagship merchandise of Cara Therapeutics, Inc.

This indicator reflects overall business efficiency by comparing net income with the total number of securities to determine the actual profit share per asset. For Cara Therapeutics Inc (TVRD), the automation of molecular target bioscreening should optimize operating expenses, which will directly impact the annual net income per share trend, allowing investors to promptly identify any hidden weakening of the issuer's fundamental position.